首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1181篇
  免费   81篇
  国内免费   18篇
耳鼻咽喉   3篇
儿科学   85篇
妇产科学   8篇
基础医学   99篇
口腔科学   27篇
临床医学   76篇
内科学   205篇
皮肤病学   27篇
神经病学   27篇
特种医学   136篇
外科学   129篇
综合类   135篇
预防医学   78篇
眼科学   8篇
药学   57篇
中国医学   39篇
肿瘤学   141篇
  2023年   8篇
  2022年   16篇
  2021年   26篇
  2020年   20篇
  2019年   16篇
  2018年   21篇
  2017年   14篇
  2016年   21篇
  2015年   31篇
  2014年   44篇
  2013年   41篇
  2012年   58篇
  2011年   49篇
  2010年   75篇
  2009年   61篇
  2008年   27篇
  2007年   32篇
  2006年   45篇
  2005年   34篇
  2004年   24篇
  2003年   26篇
  2002年   12篇
  2001年   17篇
  2000年   15篇
  1999年   26篇
  1998年   50篇
  1997年   60篇
  1996年   52篇
  1995年   44篇
  1994年   37篇
  1993年   36篇
  1992年   16篇
  1991年   11篇
  1990年   14篇
  1989年   30篇
  1988年   22篇
  1987年   20篇
  1986年   17篇
  1985年   11篇
  1984年   11篇
  1982年   11篇
  1981年   9篇
  1980年   13篇
  1977年   7篇
  1976年   8篇
  1975年   4篇
  1973年   3篇
  1972年   4篇
  1971年   3篇
  1958年   4篇
排序方式: 共有1280条查询结果,搜索用时 31 毫秒
61.
62.
This randomized controlled trial was designed to answer the question: does administration of dexamethasone to neonates with bronchopulmonary dysplasia decrease the need for assisted ventilation? Twenty-five infants with a birth weight < 1501 g, requiring mechanical ventilation and FiO2 of ± 0.30 at 21-35 days of age, were randomized to treatment with iv dexamethasone or to sham injections for 12 days. The primary outcome criterion was extubation within seven days after study entry. Treatment (n= 12) and control (n= 13) groups were well matched at entry. Dexamethasone facilitated weaning from assisted ventilation (p= 0.0154). There was no increased incidence of infection. Dexamethasone treatment resulted in a significant increase in glucosuria (p= 0.0002) and in systolic blood pressure (p= 0.0034). There was a significant decrease in heart rate (p= 0.0001) and a significant weight loss (p= 0.0002) following dexamethasone treatment. Dexamethasone treatment facilitated weaning from assisted ventilation but several systemic effects were noted that deserve further evaluation before dexamethasone becomes routine treatment.  相似文献   
63.
The effects of intermittent positive airway and continuous negative extrathoracic pressure ventilation on cerebral blood volume in preterm infants were studied using near infrared spectroscopy. In 12 infants continuous negative extrathoracic pressure caused a median decrease in cerebral blood volume of 0.14ml/100ml brain (95% confidence intervals (CI) 0.035–0.280) compared with no respiratory support. Oxygenated and deoxygenated haemoglobin also decreased, implying increased venous drainage as the main effect. In 17 infants intermittent positive pressure ventilation also caused a median reduction in cerebral blood volume of 0.06 ml/100 ml brain (95% CI 0.010–0.115) compared with endotracheal positive airway pressure. Deoxygenated haemoglobin increased by 0.07 ml/100 ml brain (95% CI 0.010–0.100) while oxygenated haemoglobin decreased by O.lOml/lOOml brain (95% CI 0.005–0.175). The increase in deoxygenated haemoglobin implies decreased venous drainage and the decrease in oxygenated haemoglobin implies that other factors may also be significant. Heart rate, blood pressure and oxygen saturation were monitored continuously and remained stable.  相似文献   
64.
目的:通过对突发性聋病人血中一氧化氮(NO)、丙二醛(MDA)、超氧化物歧化酶(SOD)含量的检洲,探讨突聋与血氧自由基和自由基的清除剂SOD之间的关系。方法:采用硝酸还原酶法测定了30例突聋病人血中NO含量,并以25例同期体检正常的健康人为对照组;同时还用硫代巴比妥酸比色法测定MDA含量,用黄嘌呤氧化酶法测定SOD含量。砖呆;应用金纳多、能量合剂、克林臭(即马来酸桂哌齐特,钙通道阻滞药)联合静脉输入,突聋各组的听力均有不同程度提高,有效率在78.57%以上。治疗后同对照组相比,血清NO、MDA水平明显低于患病之初,而SOD活性明显高于治疗之前,P〈0.01。结论;检测突聋病人血中N0、MDA、SOD的含量,能帮助我们探讨突聋的发病机理,估计预后。血氧自由基的升高可能是突聋发病因素之一,而SOD的含量可以帮助我们估计预后。  相似文献   
65.
Primary osteogenic sarcoma of the skull is an exceedingly rare condition. An adult male patient is described, who had a painless swelling in the right forehead that had rapidly enlarged in the previous 6 months. Radiological investigations showed a large destructive mass lesion involving the right side of the frontal bone with extension into the frontal sinus, causing marked extradural compression of brain parenchyma. Histopathological examination confirmed the lesion to be primary osteogenic sarcoma.  相似文献   
66.
目的研究全反式维甲酸(ATRA)及联合应用神经营养因子(BDNF,GDNF)对体外培养的神经干细胞(NSCs)分化的影响。方法取新生SD大鼠的前脑室下带(SVZ)区,按NSCs的常规培养方法分离、培养。用免疫细胞化学法鉴定巢蛋白(nestin)、微管相关蛋白-2(MAP-2)、胶质原纤维酸性蛋白(GFAP)的表达,以此来观察ATRA、BDNF、GDNF单独或联合应用对次代神经球细胞分化的作用。结果原代及次代神经球均显示nestin阳性,并可分化为MAP-2阳性神经元样细胞及GFAP阳性胶质细胞样细胞。1μmol/LATRA可促进NSCs分化为MAP-2阳性细胞的比例达(29.14&#177;5.00)%,显著高于对照组的(7.19&#177;1.21)%,差异有高度统计学意义(P〈0.001)。ATRA联合应用10ng/ml的BDNF或GDNF,与单独使用ATRA比较,并不显著提高NSCs分化为MAP-2阳性细胞的比例。结论ATRA可促进神经干细胞向神经元方向分化,ATRA联合应用BDNF或GDNF无明显的协同作用。  相似文献   
67.
The relations between age, metabolic control, disease adjustment, and psychological factors in boys and girls with recently diagnosed insulin-dependent diabetes mellitus (IDDM) were studied. Older girls had significant higher postremission glycosylated haemoglobin A (Hb Alc) levels ( p = 0.008). Girls with more hospitalizations had a lower developmental level ( p = 0.05), and had significantly more problems in the behavioural rating ( p = 0.05). Boys with more hospitalizations had a more external locus of control ( p = 0.01), more difficulties with disease adjustment, more emotional problems, and were also clinically assessed as having more behavioural problems. Boys showing more difficulties in psychological adjustment to the disease also had higher postremission Hb A1clevels ( p = 0.02). Although Swedish children with IDDM of short disease duration do not differ from healthy children in important psychological aspects, older girls and a small group of problematic younger boys are at risk of developing metabolic imbalance after a short disease duration.  相似文献   
68.
Fourteen children receiving one year of recombinant human growth hormone (rhGH) treatment underwent measurement of serial changes in body composition (measured by skinfold thickness, bioelectrical impedance, and H2(18)O dilution), resting energy expenditure (REE, estimated by ventilated hood indirect calorimetry), and total free living daily energy expenditure (TEE, measured by the doubly labelled water technique). Mean height velocity increased from 4.9 to 8.6 cm/year after six months of treatment. Fat free mass (FFM) increased more during the first six weeks (24.4 g/day) than from six to 26 weeks of treatment (6.8 g/day); fat mass decreased by 7.2 g/day and 1.1 g/day respectively. The six week increase in REE (kJ/day) was maintained after six months of treatment, though expressed per kilogram FFM (kJ/kgFFM/day), returned to pretreatment values by three months. Height velocity increases at six months correlated with six week changes in fat mass measured by skinfold thickness and REE, though use of this relationship to predict growth response in individuals is limited by the wide 95% prediction intervals. No significant changes in growth, body composition, or energy expenditure were observed between six and 12 months of treatment, in either patients who had initially responded well to treatment or those who were poor initial responders to treatment and who had their dose of rhGH doubled after six months.  相似文献   
69.
The best current model of breast cancer evolution suggests that most cancers arise from certain premalignant lesions. We have identified a common (34%) somatic mutation in the estrogen receptor (ER)-alpha gene in a series of 59 typical hyperplasias, a type of early premalignant breast lesion. The mutation, which affects the border of the hinge and hormone binding domains of ER-alpha, showed increased sensitivity to estrogen as compared with wild-type ER-alpha in stably transfected breast cancer cells, including markedly increased proliferation at subphysiological levels of estrogen. The mutated ER-alpha exhibits enhanced binding to the TIF-2 coactivator at low levels of hormone, which may partially explain its increased estrogen responsiveness. These data suggest that this mutation may promote or accelerate the development of cancer from premalignant breast lesions.  相似文献   
70.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号